Literature DB >> 21447346

Augmented neovascularization with magnetized endothelial progenitor cells in rats with hind-limb ischemia.

Hiroshi Koiwaya1, Ken-ichiro Sasaki, Takafumi Ueno, Shinji Yokoyama, Yasuyuki Toyama, Masanori Ohtsuka, Takaharu Nakayoshi, Yoshiaki Mitsutake, Tsutomu Imaizumi.   

Abstract

Augmenting neovascularization with the use of endothelial progenitor cells (EPCs) is a therapeutic option to rescue critical limb ischemia (CLI). However, the outcomes have been not so satisfactory. The detectable number of injected EPCs at the ischemic site is rather small. If EPCs accumulate more and stay longer there, neovascularization will be augmented. In this study, we tested whether external magnetic forces (EMFs) accumulated magnetized EPCs (Mag-EPCs) at the ischemic site and thereby augmented neovascularization. We cultured peripheral blood-derived mononuclear cells to obtain EPCs and generated Mag-EPCs by a magnetofection method with nanoparticles. Prussian-blue staining revealed magnetic nanoparticles incorporated into the cytoplasms and nuclei of Mag-EPCs. The survival rate of Mag-EPCs at day 9 of culture was 98.7%, indicating no cell toxicity of magnetic nanoparticles. EMFs augmented adhesion capacity of Mag-EPCs not only in the static but also in the flow condition in vitro, compared to without EMFs. The migration capacity of Mag-EPCs with EMFs was 160% more than EPCs or Mag-EPCs without them. After an intravenous injection of Mag-EPCs into the rat with hind-limb ischemia, the recovery of blood flow and capillary density in the ischemic limb were significantly more (p<0.01) with EMFs than without them. EMFs augmented neovascularization capacity of Mag-EPCs compared to EPCs alone. This method could be a new therapeutic strategy for patients with CLI.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21447346     DOI: 10.1016/j.yjmcc.2011.03.012

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  7 in total

1.  Transplantation of bradykinin-preconditioned human endothelial progenitor cells improves cardiac function via enhanced Akt/eNOS phosphorylation and angiogenesis.

Authors:  Zu-Long Sheng; Yu-Yu Yao; Ye-Fei Li; Cong Fu; Gen-Shan Ma
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

Review 2.  Nanoscale strategies: treatment for peripheral vascular disease and critical limb ischemia.

Authors:  Chengyi Tu; Subhamoy Das; Aaron B Baker; Janeta Zoldan; Laura J Suggs
Journal:  ACS Nano       Date:  2015-04-10       Impact factor: 15.881

Review 3.  Secreted proteins as a fundamental source for biomarker discovery.

Authors:  Miroslava Stastna; Jennifer E Van Eyk
Journal:  Proteomics       Date:  2012-01-19       Impact factor: 3.984

4.  Transplantation of bradykinin-preconditioned human endothelial progenitor cells improves cardiac function via enhanced Akt/eNOS phosphorylation and angiogenesis.

Authors:  Zu-Long Sheng; Yu-Yu Yao; Ye-Fei Li; Cong Fu; Gen-Shan Ma
Journal:  Am J Transl Res       Date:  2015-07-15       Impact factor: 4.060

5.  Magnetic Nanoparticles Conjugated with Peptides Derived from Monocyte Chemoattractant Protein-1 as a Tool for Targeting Atherosclerosis.

Authors:  Chung-Wei Kao; Po-Ting Wu; Mei-Yi Liao; I-Ju Chung; Kai-Chien Yang; Wen-Yih Isaac Tseng; Jiashing Yu
Journal:  Pharmaceutics       Date:  2018-05-24       Impact factor: 6.321

6.  Silica-coated magnetic nanoparticles labeled endothelial progenitor cells alleviate ischemic myocardial injury and improve long-term cardiac function with magnetic field guidance in rats with myocardial infarction.

Authors:  Bo-Fang Zhang; Hong Jiang; Jing Chen; Qi Hu; Shuo Yang; Xiao-Pei Liu
Journal:  J Cell Physiol       Date:  2019-04-14       Impact factor: 6.384

7.  FOXO4-knockdown suppresses oxidative stress-induced apoptosis of early pro-angiogenic cells and augments their neovascularization capacities in ischemic limbs.

Authors:  Takaharu Nakayoshi; Ken-Ichiro Sasaki; Hidemi Kajimoto; Hiroshi Koiwaya; Masanori Ohtsuka; Takafumi Ueno; Hidetoshi Chibana; Naoki Itaya; Masahiro Sasaki; Shinji Yokoyama; Yoshihiro Fukumoto; Tsutomu Imaizumi
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.